Agreed. This decision is 100% positive for IHL’s clinical...

Agreed. This decision is 100% positive for IHL’s clinical programs.

Australia has one of the best platforms for research in the World and so the greatest commercial advantage is a highly restrictive environment for psychedelics. This creates a high barrier of entry to new players and creates a run way for an advanced company like IHL to develop and protect their IP. The last thing you want at the moment is a deregulated system that allows “bad apples” to attempt to monitize a sector before the science is mature.

It’s a sensible decision from the TGA and ensures that money is efficiently invested into the scientific development of the sector, companies like IHL partnering with real scientists like Dr Liknaitzky.

I’ve got no doubt that the TGA will down schedule these drugs in time but IHL’s biggest commercial market will be the US ultimately anyway.